Thank you for sending in questions and feedback!

Every Saturday I respond to reader emails in the AskDavis@paradigmpressgroup.com inbox.

Here are my responses to this week’s batch:

Explain to me why I see the numbers for SpaceX being the opposite of your words. All the reported numbers are higher than the expected numbers. What am I missing? – Crystal

Hi, Crystal. I believe you’re referring to the fact that SpaceX reported earnings above expectations, yet the stock still dropped.

Here's what SpaceX delivered:

Revenue: $7.81 billion vs. $6.93 billion expected

Loss per share: 9 cents.

Here’s how the company’s three segments performed:

Space: $962 million vs. $835 million expected

Connectivity: $4.29 billion vs. $3.83 billion expected

AI: $2.56 billion vs. $2.18 billion expected

This actually happens pretty frequently – good earnings and yet the stock still drops.

With SpaceX specifically, investors reacted negatively to capital expenditures jumping sixfold from a year earlier to $18.4 billion in the quarter. Most of that – $15.83 billion – was in AI.

This is the biggest knock on SpaceX right now.

Investors wanted a space company.

Instead, they got an AI company spending tens of billions of dollars to compete with OpenAI, Anthropic, and some of the other most well-funded and talented companies on the planet.

Can AST take business from SpaceX’s Starlink? – Brett

Yes! But it’s a bit nuanced.

Starlink's core business is broadband internet delivered through satellite dishes at homes, businesses, ships, and airplanes.

AST SpaceMobile is taking a different approach. It partners with carriers like AT&T, Verizon, and Vodafone to connect ordinary smartphones directly to satellites – no special hardware required.

Starlink's Direct-to-Cell service is rolling out text, voice, and data. AST, on the other hand, is built specifically for high-speed cellular broadband.

I don't think AST replaces Starlink's home internet business. But if it successfully scales its network, it could become a serious competitor in direct-to-cell mobile broadband – where the two companies are increasingly going head-to-head.

I read your fun and informative article on options. However, the only example you gave was with Meta. So in order to make your $300 in 10 minutes, I guess that means you sold a bunch of covered calls on a bunch of stocks. I don’t think you ever actually specifically addressed that. Anyhow, I still enjoyed the article. Keep up the good work and enjoy your summer, my friend. – Dave

Hi, Dave. Here’s a link to the article for people wondering.

Towards the end I list all the options I sold that morning.

Meta: $40, Nvidia: $100, Uber Technologies: $30, AMD: $30, Starbucks: $30, Lithium Americas: $50, GameStop: $30.

I hope this helps.

What are your thoughts about trying to pick AI related medical stocks in general or any of the names in my list in specific? I own: AZN, MRNA, BSX, TEM, BFLY, QTRX, MDT, HYFT, LTRN, VKTX, PYNKF, QNTM. Note: My list started out small, but I kept finding more that drew my interest, so it snowballed a bit. – Andrea

Andrea, I reached out to Ray Blanco for his thoughts on your question. Ray is our in-house expert in this field.

Ray Blanco: Great question, Andrea. It's an exciting space.

The funny thing about "medical AI" is that it isn't really a standalone sector anymore. Nearly every healthcare company is using AI in some way.

What matters most isn't the AI itself. It's the data. Algorithms can be copied. Proprietary datasets can't. That's why I like companies that own unique clinical or research data. Tempus is a great example with its massive cancer, genomic, and patient outcomes database.

As for your holdings:

• AZN, MDT, BSX: High-quality companies using AI to improve existing businesses. Own them for their pipelines, devices, and cash flow—not AI alone.

• MRNA, VKTX: Clinical catalyst stocks. Their futures depend on trial results. (I personally own VKTX.)

• QTRX: More of a diagnostics tools company than an AI play.

• BFLY: Handheld ultrasound with AI-assisted imaging.

• LTRN: Probably the purest AI drug-discovery company on your list, but still a high-risk biotech.

AZN and MDT won't 10x. Keep them if you want them. They’re quality names. But just count them separately from the shot-on-goal names, and size the small ones so no single failure hurts and no single winner is too small to matter.

What do you think will happen to Cameco (CCJ) when Westinghouse goes public? Will CCJ still own 49% of the company? – Jeanette

Hi, Jeanette. This isn’t a stock that I follow closely.

But I see that CCJ owns 49% of Westinghouse and Westinghouse just filed paperwork to IPO.

When that happens, Westinghouse will likely sell new shares to the public – diluting existing shareholders.

So yes, CCJ will still own a significant stake in Westinghouse post-IPO. But it won’t be 49%. It will likely be anywhere from 30-45%.

Important Update: The Million Mission website is live!

I constantly get questions regarding where to find previous alerts. Well, The Million Mission website is live and you can check out archived alerts here.

Portfolio Overview

Here’s what I’m currently holding in The Million Mission portfolio:

Fannie Mae (FNMA) – 3,500 shares @ $6.86/share

Uber Technologies (UBER) – 200 shares @ $80/share

Nvidia (NVDA) – 200 shares @ $179/share

Micron (MU) – 50 shares @ $935/share